Citations

Clear

342 citation(s) found for "Si, Ting".

Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer
Moding, Everett J. , Esfahani, Mohammad Shahrokh , Jin, Cheng , Hui, Angela B. , Nabet, Barzin Y. , Liu, Yufei , Chabon, Jacob J. , Binkley, Michael S. , Kurtz, David M. , Hamilton, Emily G. , Chaudhuri, Aadel A. , Liu, Chih Long , Bonilla, Rene F., Jiang, Alice L. , Lau, Brianna , Lopez, Pablo , He, Jianzhong, Qiao, Yawei, Yao, Luyang , Gandhi, Saumil , Das, Millie , Ramchandran, Kavitha , Padda, Sukhmani K. , Neal, Joel W. , Wakelee, Heather A. , Li, Ruijiang , Alizadeh, Ash A. , Shahrokh Esfahani, Mohammad , Li, Zhe , Bonilla, Rene F , Jiang, Alice L , Lau, Brianna C , Lopez, Pablo , He, Jianzhong , Qiao, Yawei , Xu, Ting , Yao, Luyang , Gandhi, Saumil , Liao, Zhongxing , Das, Millie , Ramchandran, Kavitha J , Padda, Sukhmani K , Neal, Joel W , Wakelee, Heather A , Gensheimer, Michael F , Loo, Billy W , Li, Ruijiang , Lin, Steven H , Alizadeh, Ash A , Diehn, Maximillian , Binkley, Michael Sargent , Kurtz, David M , Loo, Billy W. , Lin, Steven H. , Diehn, Maximilian

Mayo Clinic

Cancer Discovery | April 29, 2025 | Volume: 15 | Issue: 8 | Pages: 1609-1629

10.1158/2159-8290.cd-24-1704 | PMID 40299851 Get It

Abstract The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Tzeng, Sheue‐Fen , Yu, Yi-Ru , Park, Jaeoh , Renesse, Janusz von , Hsiao, Huey-Wen , Hsu, Chen-Hsuan , Garnica, Josep , Chen, Jintian , Chiu, Lu-Ting , Santol, Jonas , Chen, Tse-Yu , Chung, Pei-Han , Meng, Zhen , Lin, Yun-Han, Tsai, Chin‐Hsien , von Renesse, Janusz , Kandalaft, Lana E , Starlinger, Patrick , Hsieh, Rodney Cheng-En , Yu, Ming-Chin , Hsiao, Pei-Wen , Carmona, Santiago J , Chen, Hung-Kai , Meng, Zhen , Lin, Yun-Han , Zhou, Jingying , Tsai, Chin-Hsien , Ho, Ping-Chih , Santol, Jonas , Starlinger, Patrick , Hsieh, Cheng‐En

Mayo Clinic

Cancer Discovery | April 28, 2025 | Volume: 15 | Issue: 8 | Pages: 1676-1696

10.1158/2159-8290.cd-24-1409 | PMID 40294022 Get It

Abstract Tumor cells develop various strategies to evade immune surveillance, one of which involves altering the metabolic state of the tumor microenvironment. In response to metabolic stress in the tumor microenvironment, several tumor-infiltrating immune subsets upregulate CD36 to take up lipids. This leads to impaired antitumor immunity, as intratumoral regulatory T cells exhibit increased survival and suppressive activity, whereas CD8+ T cells become more susceptible to ferroptosis and exhaustion. In this study, we develop a humanized anti-CD36 IgG4 antibody, PLT012, against the lipid-binding domain of CD36 with excellent safety and favorable pharmacokinetic features in mice and cynomolgus monkeys. PLT012 alone or in combination with PD-L1 blockade or standard-of-care immunotherapy results in robust antitumor immunity in both immunotherapy-sensitive and -resistant hepatocellular carcinomas (HCC). Notably, PLT012 also reprograms the immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 reprograms antitumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36. Significance: Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.
Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021
Huang, Xiaoquan , Ye, Sitao, Cheryala, Mahesh, Chen, Shiyao , Wang, Yichen , Tian, Li , Huang, Yu-Ting

Mayo Clinic

Chinese Medical Journal | April 25, 2025 | Volume: 138 | Issue: 22 | Pages: 2947-2954

10.1097/cm9.0000000000003517 | PMID 40280878 Get It

Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is a common liver disease and may become the leading cause of severe liver disease in the future. The Global Burden of Disease (GBD) study assesses MAFLD’s impact in countries and regions worldwide, providing insights into its prevalence. Methods: Prevalence data for MAFLD from 1990 to 2021 by country and region in all sex and age groups were collected from the Global Health Data Exchange. The categorization of countries and geographic areas by development was performed using the Sociodemographic Index (SDI). Results: Between 1990 and 2021, the global crude prevalence rate of MAFLD increased from 10.6% to 16.1% (beta-coefficient: 0.2%, 95% confidence interval [CI]: 0.2–0.2%, P <0.001), and the age-standardized prevalence rate was increased from 12.1% to 15.0% (beta-coefficient: 0.1%, 95% CI: 0.1–0.1%, P <0.001). In 2021, MAFLD was estimated to have affected 1.3 billion people worldwide. Significant uptrends were observed in all regions, super regions, and SDI categories. The fastest increase from 1990 to 2021 and the highest prevalence rate in 2021 were experienced by countries and territories with high–middle and middle SDI. An increase in the prevalence of MAFLD from 1990 to 2021 was demonstrated in all but six countries. Conclusions: In 2021, the number of patients affected by MAFLD was doubled compared to 1990, and the prevalence rate increased by over 50%. The burden of MAFLD, as measured by prevalence, was more prominent in countries and territories with middle SDI and in those located in North African and Middle Eastern, possibly due to changes in lifestyle in these areas over the past 30 years.
ATG9 inhibits Rickettsia binding to the host cell surface by blocking the rOmpB-XRCC6/KU70 interaction
Chen, Chen , Liu, Guoxu , Xu, Kehan , Chen, Aibao, Cheng, Ziyang, Yan, Xueping, Zhang, Ting , Sun, Yan, Wang, Jiayao, Luo, Shuangshuang , Zhou, Weiting, Yang, Yanan , Yang, Yanan , Liu, Guoxu, Cheng, Ziyang, Yan, Xueping, Tian, Yu , Wang, Jiayao, Zhou, Weiting, Deng, Sheng‐Qun , Liu, Yan

Mayo Clinic

Autophagy | April 22, 2025 | Volume: 21 | Issue: 10 | Pages: 2213-2229

10.1080/15548627.2025.2496363 | PMID 40259479 Get It

Abstract 1380: Role of cytokine-induced cell death on efficacy of teclistamab-mediated T cell killing of multiple myeloma cells
Carr, Allison, Ting, Adrian T.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1380-1380

10.1158/1538-7445.am2025-1380 Get It

Abstract Multiple myeloma (MM) is the second most common hematologic malignancy among US adults, characterized by high rates of relapse and refractory disease. Anti-Myeloma T cell immunotherapies, such as chimeric antigen receptors (CAR-Ts) and bispecific T cell engagers (BiTEs), have been able to induce deep responses in the clinic and extending survival for many. However, even these responses are not durable and majority of patients still relapse. MM cell signaling in response to cytokines released by these T cells, such as Tumor Necrosis Factor (TNF) Alpha, and Interferon gamma (IFNγ), may offer additional insight into mechanisms of relapse and resistance as well as avenues of therapeutic manipulation. To evaluate the effects of TNF and IFNγ on MM cell death and proliferation, we obtained human MM cell lines (MMCLs) and stably transduced them with a GFP-NLS reporter. We then monitored these cell lines in the presence of TNF, IFNγ, or TNF+IFNγ and tracked their cell death and growth kinetics over time using DiYO-3 incorporation and GFP count, respectively, via IncuCyteS3 live cell imaging. We next utilized Teclistamab, a B cell maturation antigen (BCMA)-directed BiTE, to co-culture MMCLs with healthy donor derived T cells at various effector to target (E:T) ratios and monitored for T cell mediated death again via IncuCyteS3 live cell imaging. While all MMCLs were able to be killed at high E:T ratios (1:1), only cytokine-sensitive lines remained susceptible to T cell killing at lower E:T ratios (1:10). The addition of TNF and/or IFNγ blocking antibodies confirmed that the increased sensitivity of these lines to T cell killing was indeed mediated by the two cytokines. In summary, were able to show an in vitro model of differential MM cell response to Teclistamab mediated T cell killing, and that this difference in response was predicated on the MM cells’ baseline sensitivity to cytokine mediated cell death via TNF and IFNγ. Thus, further dissecting mechanisms underlying resistance or sensitivity of MM cells to cytokine induced death could suggest therapeutic targets with the potential to enhance the efficacy of anti-MM T cell immunotherapies. Citation Format: Allison Carr, Adrian Ting. Role of cytokine-induced cell death on efficacy of teclistamab-mediated T cell killing of multiple myeloma cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1380.
Abstract 2470: Transforming cancer diagnosis with digital chemical pathology
Oh, Ji-Hun , Liu, Yen‐Ting , Ho, Ruo-Jing , Sharma, Ishaan , Orr, Andres C., Tamonis, Mykolas, Cheville, John C. , Falahkheirkhah, Kianoush , Yeh, Kevin L. , Confer, Matthew P. , Bhargava, Rohit

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2470-2470

10.1158/1538-7445.am2025-2470 Get It

Pathology remains a labor-intensive discipline, relying on workflows rooted in practices established over a century ago. Despite incremental technological advancements, the diagnostic process—from tissue preparation to interpretation—still heavily depends on thinly sliced tissue sections stained and examined under brightfield microscopy by skilled pathologists. Difficult cases often necessitate iterative staining or complex immunohistochemistry (IHC) analyses. However, the recent emergence of machine learning (ML) presents an opportunity to revolutionize traditional diagnostic workflows. One promising advancement is Digital Chemical Pathology (DCP), a paradigm that combines modern ML algorithms with infrared (IR) imaging to streamline pathology and enhance diagnostic accuracy. Infrared wavelengths inherently align with molecular vibrational frequencies, providing intrinsic contrast based on the chemical composition of samples. Mid-IR spectroscopic microscopes leverage this principle to spatially resolve molecular distributions at the pixel level, creating "chemical fingerprints" that ML algorithms can correlate with cellular identities and disease states. Recent advancements, particularly the development of broadly tunable quantum cascade lasers (QCLs), have enabled faster IR imaging, paving the way for clinical applications of IR spectroscopic microscopes. In this research, we demonstrate the potential of DCP using frozen tissue samples. Our approach focuses on two core tasks: (1) virtual staining, translating IR images into realistic, stained images interpretable by pathologists, and (2) tissue segmentation, enabling the automated detection of cancer and the distinction between normal and cancerous tissues. Furthermore, we incorporate statistical safety algorithms to generate uncertainty maps, ensuring the reliability of predictions. Our findings highlight that the integration of IR imaging and ML can facilitate automated diagnostics, providing pathologists with powerful tools for enhanced healthcare delivery. By leveraging DCP, we aim to modernize pathology workflows, reduce diagnostic turnaround times, and improve patient outcomes through precise and efficient analysis. Citation Format: Kianoush Falahkheirkhah, Kevin Yeh, Ji-Hun Oh, Yen-Ting Liu, Ruo-Jing Ho, Ishaan Sharma, Matthew Confer, Andres Orr, Mykolas Tamonis, John Cheville, Rohit Bhargava. Transforming cancer diagnosis with digital chemical pathology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2470.
CD27 and ICOS as targets of PD-1/PD-L1 signaling to regulate resident memory CD8+ T cells mediated pulmonary protection and pathology
Chen, Yuanyuan , Pan, Tao , Pan, Jianli, Zhao, Sheng , Shang, Ting , Xu, Hong’en , Lv, Xing , Kang, Fei , Zhao, Feng , Wang, Zheng , Wang, Zhenzhen , Song, Liqiang , Zhang, Hang , Li, Jing , Nie, Yongzhan , Shi, Lei

Mayo Clinic

No container title available | April 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6316326/v1 Get It

Abstract While tissue-resident memory CD8+ T cells (TRM cells) provide superior frontline defense against pathogens, the molecular mechanisms governing their persistence and functional regulation remain poorly defined. Our study reveals that the costimulatory receptors CD27 and ICOS coordinately sustain PD-1high CD8+ TRM cell populations following resolution of acute influenza infection. These costimulatory signals serve as critical targets for PD-1/PD-L1 blockade, thereby facilitating the rejuvenation of PD-1high TRM cells and influencing the progression of fibrotic sequelae during the memory phase. Mechanistic dissection identifies the nuclear receptor Nur77 (NR4A1) as the convergent transcriptional hub downstream of CD27/ICOS, governing proliferative renewal and maintenance of PD-1high TRM cells. Therapeutic administration of a CD27 agonist not only amplified this TRM cell subset in late-stage memory but also conferred cross-protective immunity against heterosubtypic viral challenges. Clinically, the expression of CD27 and ICOS is enriched in CD8+ T cells within the lung tissues of patients with pulmonary fibrosis. Collectively, our findings establish the "CD27/ICOS-NR4A1-Proliferation" axis as a linchpin of PD-1/PD-L1-mediated TRM cell homeostasis, revealing druggable targets for intercepting infection-associated fibrotic progression.
Authors' Reply: Association between CKD and Kidney Stones: A Reliable Relationship?
Zhou, Le‐Ting , Jayachandran, Muthuvel , Larson, Nicholas B. , Lieske, John C. , Lieske, John C , Larson, Nicholas B

Mayo Clinic

Journal of the American Society of Nephrology | March 26, 2025 | Volume: 36 | Issue: 6 | Pages: 1229-1229

10.1681/asn.0000000679 | PMID 40137859 Get It

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+
Sklavenitis‐Pistofidis, Romanos , Lightbody, Elizabeth D. , Reidy, Mairéad, Tsuji, Junko , Alberge, Jean-Baptiste , Aranha, Michelle P. , Heilpern-Mallory, Daniel , Huyng, Daisy, Chong, Stephen Jun Fei , Chung, Anna Y., Zhang, Jeremy, Hackett, Liam , Wu, Ting , Berrios, Brianna, Belkin, Saveliy , Dutta, Ankit K. , Knudson, Ryan A., Brandt, Carolyn, Papaioannou, Maria , Manier, Salomon , Hackett, Liam , Haradhvala, Nicholas J , Wu, Ting , Su, Nang K , Belkin, Saveliy , Dutta, Ankit K , Greipp, Patricia T , Ghobrial, Irene M , Manier, Salomon , Sklavenitis-Pistofidis, Romanos , Alberge, Jean-Baptiste , Roweth, Harvey G. , Huynh, Daisy , Chung, Anna Y., Su, Nang Kham , Brandt, Carolyn, Greipp, Patricia T. , Davids, Matthew S. , Getz, Gad , Ghobrial, Irene M.

Mayo Clinic

Blood | March 12, 2025 | Volume: 146 | Issue: 1 | Pages: 89-103

10.1182/blood.2024025102 | PMID 40073369 Get It

Abstract The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.
Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae
Wei, Xiaoqin , Qian, Wei , Narasimhan, Harish , Chan, T. K., Liu, Xue , Arish, Mohd , Young, Scott , Li, Chaofan , Cheon, In Su , Yu, Qing , Santos, Gislane de Almeida , Yeatts, Eric V., Spear, Olivia J., Yi, Mou, Hahn, Young S. , Kaplan, Mark H. , Sperling, Anne I. , Shim, Yun M. , Vassallo, Robert , Chen, Peter , Roden, Anja C. , Que, Jianwen , Chan, Ting , Young, Samuel , de Almeida Santos, Gislane , Zhao, Xiao-Yu , Yeatts, Eric V , Parimon, Tanyalak , Fang, Yinshan , Hahn, Young S , Bullock, Timothy N J , Somerville, Lindsay A , Kaplan, Mark H , Sperling, Anne I , Shim, Yun Michael , Vassallo, Robert , Chen, Peter , Ewald, Sarah E , Roden, Anja C , Que, Jianwen , Jiang, Dianhua , Sun, Jie , Li, Chaofan , Yi, Megan, Somerville, Lindsay , Sun, Jie

Mayo Clinic

Science | March 6, 2025 | Volume: 387 | Issue: 6738 | Pages: No page available

10.1126/science.adq2509 | PMID 40048515 Get It

Peroxisomes are vital but often overlooked metabolic organelles. We found that excessive interferon signaling remodeled macrophage peroxisomes. This loss of peroxisomes impaired inflammation resolution and lung repair during severe respiratory viral infections. Peroxisomes were found to modulate lipid metabolism and mitochondrial health in a macrophage type-specific manner and enhanced alveolar macrophage-mediated tissue repair and alveolar regeneration after viral infection. Peroxisomes also prevented excessive macrophage inflammasome activation and IL-1β release, limiting accumulation of KRT8 high dysplastic epithelial progenitors following viral injury. Pharmacologically enhancing peroxisome biogenesis mitigated both acute symptoms and post-acute sequelae of COVID-19 (PASC) in animal models. Thus, macrophage peroxisome dysfunction contributes to chronic lung pathology and fibrosis after severe acute respiratory syndrome coronavirus 2 infection.